Global Topical Drug Delivery Market is expected to reach USD 205.1 billion by 2024 from USD 101.7 billion in 2016, growing at a CAGR of 9.2% in the forecast period 2017 to 2024.
- Advertising -
The market for "global topical drug delivery market" is estimated to reach USD 205.1 billion by 2024 from USD 101.7 billion in 2016, growing at a CAGR of 9.2% in the forecast period 2017 to 2024.
Request for Report @: databridgemarketresearch.com/request-a-sample/?dbmr=global-topical-drug-delivery-market
The global topical drug delivery market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Galderma Pharma, S.A., dominated the topical drug delivery market accounting for a highest market share in 2016, followed by Bayer AG, and Valeant Pharmaceuticals.
Other players in this market include Allergen Plc.
- Advertising -
Some of the other players in the global topical drug delivery market are MedPharm, Janssen Pharmaceuticals, Inc. (A J&J Company), Crescita Therapeutics, West Pharmaceutical Services, Biofarmitalia s.r.l, Pharmatek Laboratories, Inc., Stiefel Laboratories, Inc., Tapemark, Acrux Limited, Nitto Denko Corporation, Skinvisible Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Pocono Coated Products LLC, TheraSolve NV., Samyang Biopharmaceuticals Corporation, Lohmann Therapie-Systeme AG, Prosollus Pharmaceuticals, Easton Pharmaceuticals Inc., Novosis AG, Endo Pharmaceuticals Inc., Transdermal Technologies, Inc., Sheffield Pharmaceuticals, Inc., and Solvay among others.
Galderma Pharma S.A.
Galderma Pharma S.A. was incorporated in 1981, as a joint between Nestle and L'Oreal. In February, 2014 Nestle SA, entered into an agreement to acquire remaining 50% stake in the company, from L'Oreal S.A.
After the completion of the acquisition the company will form the foundation of Nestle Skin Health S.A. Galderma Pharma S.A. is headquartered in Lausanne Switzerland.
Inquiry for TOC Visit @: databridgemarketresearch.com/toc/?dbmr=global-topical-drug-delivery-market
- In July 2016, Galderma announces fda approval of full prescription-strength differin gel for over-the-counter acne use.
- In July 2016, Galderma announces approval of epiduo gel for the treatment of acne in Japan.
Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG is a provider of healthcare, nutrition, and high-technology materials and services. The company has three business segments, namely, HealthCare, Crop Science, and Material Science.
- On July 2015, the U.S. Food and Drug Administration (FDA) approved Finacea Foam, for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
Valeant Pharmaceuticals International, Inc.
Founded in 1994 and headquartered in Quebec, Canada, Valeant Pharmaceuticals International, Inc. is a pharmaceutical company which engages in developing, manufacturing, and marketing pharmaceutical products in the areas of dermatology, eye health, neurology, and generics.
- In August 2016, Valeant announced the re-launch of its generic ofloxacin otic solution to treat bacterial ear infections. The product was temporarily discontinued in April 2015 due to an issue concerning the active pharmaceutical ingredient supplier, which has been resolved.
Read more about the Global Topical Drug Delivery Market @: databridgemarketresearch.com/reports/global-topical-drug-delivery-market/
Category: Market Research Publishers and RetailersCompany profile: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wi ...
For more information: